Walmart will provide over 250 prescription drugs, including certain GLP-1 medications, inhalers, and insulin, free of charge to its employees.
Walmart confirmed to CNBC on Tuesday that it plans to offer over 250 prescription drugs for free to its employees by 2027, including certain insulins, inhalers, and GLP-1 drugs for diabetes treatment. This move is part of the company's expanded employee benefits, aimed at attracting and retaining talent. Among these, Novo Nordisk's Ozempic and Eli Lilly's Mounjaro will be provided free of charge to patients with type 2 diabetes after a new prior authorization process. However, Walmart will still not cover GLP-1 drugs used for weight loss purposes.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
China's futures exchanges to tighten leash on quant trading, defining violations and punishments
-
2
Dutch pensions manager PGGM agrees to take on part of the risk on €5 billion of ING loans backing energy transition
-
3
Goldman Sachs: U.S. Stock Market Sees Worst Internal Divergence Since Pandemic, Institutions "Panic-Rushing into Value Stocks" Leads to Sharp Reversal in Tech Flows
-
4
Iran escalates attacks on "non-compliant" oil tankers, putting crude oil shipments through the Strait of Hormuz under pressure, with multiple empty VLCCs avoiding the Persian Gulf.
-
5
Meta releases flagship AI model Muse Wonder, outperforming GPT-6 Astra and Claude Opus 5.5 in performance tests.
-
6
Intel and Broadcom CEOs warn that capital is the biggest bottleneck for AI, with Broadcom's CEO stating some investors are "gambling in a casino"; Musk responds: Don't cry when you're in a casino.
-
7
Samsung Electronics and SK Hynix shares fell due to concerns over Chinese competitors and comments from Broadcom.
-
8
TD Cowen: CFTC's New Crypto Regulatory Framework May Face Deadline Due to 2028 Election
-
9
BlackRock, the world's largest asset manager, has adjusted its core allocation: overweighting short-term U.S. Treasuries, and downgrading U.S. equities and MBS to neutral.
-
10
Canton Network records over $155 million in Q3 fees, CertiK says
Markets Today
Recommended Reading


